Targeting the histidine pathway in Mycobacterium tuberculosis

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Tuberculosis (TB) remains a major global health challenge, causing significant morbidity and mortality.
• The rise of drug-resistant Mycobacterium tuberculosis (Mtb) strains and HIV co-infection necessitates new therapeutic strategies.
• The L-histidine biosynthetic pathway is a validated essential pathway in Mtb, absent in humans, presenting a unique drug target.

Purpose of the Study:

• To provide a comprehensive overview of enzymes within the Mtb L-histidine biosynthetic pathway as potential drug targets.
• To summarize existing inhibition data for Mtb or orthologous histidine pathway enzymes.
• To highlight the potential for developing novel antimycobacterial agents targeting this pathway.

Main Methods:

• Literature review of studies focusing on the L-histidine biosynthetic pathway in Mtb.
• Analysis of enzymatic steps and substrate utilization within the pathway.
• Compilation and summary of reported inhibition data for key enzymes.

Main Results:

• The L-histidine pathway comprises ten enzymatic steps, converting 5-phosphoribosyl 1-pyrophosphate to L-histidine.
• Enzymes in this pathway are crucial for Mtb growth in vitro.
• The pathway's absence in mammals offers a window for selective toxicity of potential drugs.

Conclusions:

• Enzymes of the Mtb L-histidine biosynthetic pathway are attractive targets for novel antitubercular drug development.
• Targeting this essential pathway holds promise for overcoming drug resistance and improving TB treatment.
• Further research into specific enzyme inhibitors could lead to effective new antimycobacterial agents.